232 related articles for article (PubMed ID: 22480225)
1. Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Schultz CR; Golembieski WA; King DA; Brown SL; Brodie C; Rempel SA
Mol Cancer; 2012 Apr; 11():20. PubMed ID: 22480225
[TBL] [Abstract][Full Text] [Related]
2. PTEN suppresses SPARC-induced pMAPKAPK2 and inhibits SPARC-induced Ser78 HSP27 phosphorylation in glioma.
Alam R; Schultz CR; Golembieski WA; Poisson LM; Rempel SA
Neuro Oncol; 2013 Apr; 15(4):451-61. PubMed ID: 23382286
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma.
McClung HM; Golembieski WA; Schultz CR; Jankowski M; Schultz LR; Rempel SA
Carcinogenesis; 2012 Feb; 33(2):275-84. PubMed ID: 22114076
[TBL] [Abstract][Full Text] [Related]
4. HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion.
Golembieski WA; Thomas SL; Schultz CR; Yunker CK; McClung HM; Lemke N; Cazacu S; Barker T; Sage EH; Brodie C; Rempel SA
Glia; 2008 Aug; 56(10):1061-75. PubMed ID: 18442089
[TBL] [Abstract][Full Text] [Related]
5. PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.
Thomas SL; Alam R; Lemke N; Schultz LR; Gutiérrez JA; Rempel SA
Neuro Oncol; 2010 Sep; 12(9):941-55. PubMed ID: 20472716
[TBL] [Abstract][Full Text] [Related]
6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
7. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
8. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
9. Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Sang DP; Li RJ; Lan Q
Acta Pharmacol Sin; 2014 Jun; 35(6):832-8. PubMed ID: 24902789
[TBL] [Abstract][Full Text] [Related]
10. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch.
Hayashi N; Peacock JW; Beraldi E; Zoubeidi A; Gleave ME; Ong CJ
Cell Death Differ; 2012 Jun; 19(6):990-1002. PubMed ID: 22179576
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells.
Liu H; Zhang H; Jiang X; Ma Y; Xu Y; Feng S; Liu F
Cancer Biother Radiopharm; 2011 Dec; 26(6):705-15. PubMed ID: 22145659
[TBL] [Abstract][Full Text] [Related]
12. HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2.
Qi S; Xin Y; Qi Z; Xu Y; Diao Y; Lan L; Luo L; Yin Z
Cell Signal; 2014 Mar; 26(3):594-602. PubMed ID: 24308965
[TBL] [Abstract][Full Text] [Related]
13. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
Shi Q; Bao S; Song L; Wu Q; Bigner DD; Hjelmeland AB; Rich JN
Oncogene; 2007 Jun; 26(28):4084-94. PubMed ID: 17213807
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
16. LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Liao Y; Shen L; Zhao H; Liu Q; Fu J; Guo Y; Peng R; Cheng L
J Cell Biochem; 2017 Jul; 118(7):1889-1899. PubMed ID: 28121023
[TBL] [Abstract][Full Text] [Related]
17. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of AKT induced by phosphorylated Hsp27 confers the apoptosis-resistance in t-AUCB-treated glioblastoma cells in vitro.
Li R; Li J; Sang D; Lan Q
J Neurooncol; 2015 Jan; 121(1):83-9. PubMed ID: 25200832
[TBL] [Abstract][Full Text] [Related]
19. Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Chio CC; Tai YT; Mohanraj M; Liu SH; Yang ST; Chen RM
Phytomedicine; 2018 Oct; 49():41-51. PubMed ID: 30217261
[TBL] [Abstract][Full Text] [Related]
20. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
